Your browser is no longer supported. Please, upgrade your browser.
Settings
DCTH Delcath Systems, Inc. daily Stock Chart
DCTH [NASD]
Delcath Systems, Inc.
Index- P/E- EPS (ttm)-10.07 Insider Own4.60% Shs Outstand2.48M Perf Week-7.56%
Market Cap0.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.05M Perf Month-60.67%
Income-14.60M PEG- EPS next Q-3.24 Inst Own24.20% Short Float36.05% Perf Quarter-91.33%
Sales1.80M P/S0.22 EPS this Y50.50% Inst Trans36.97% Short Ratio0.19 Perf Half Y-95.90%
Book/sh2.95 P/B0.05 EPS next Y- ROA-54.70% Target Price16.00 Perf Year-99.77%
Cash/sh1.49 P/C0.11 EPS next 5Y15.00% ROE-221.10% 52W Range0.13 - 110.08 Perf YTD-82.47%
Dividend- P/FCF- EPS past 5Y45.60% ROI-176.90% 52W High-99.85% Beta1.56
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin72.90% 52W Low23.60% ATR0.06
Employees35 Current Ratio1.10 Sales Q/Q0.00% Oper. Margin- RSI (14)23.84 Volatility23.10% 20.81%
OptionableYes Debt/Eq1.42 EPS Q/Q66.40% Profit Margin- Rel Volume1.01 Prev Close0.17
ShortableYes LT Debt/Eq1.42 EarningsMar 20 BMO Payout- Avg Volume3.99M Price0.16
Recom2.00 SMA20-37.19% SMA50-73.81% SMA200-99.17% Volume4,045,368 Change-5.01%
Jun-08-10Initiated BioLogic Equity Research Sell
Apr-22-10Reiterated Wedbush Outperform $7.50 → $21
Apr-22-10Initiated Roth Capital Buy $15
Nov-30-09Initiated Wedbush Morgan Outperform
Jun-10-08Initiated Canaccord Adams Buy $2.65
Feb-23-17 08:04AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -9.82%
Feb-22-17 04:28PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +10.76%
08:00AM  Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies GlobeNewswire
Feb-21-17 08:00AM  Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy GlobeNewswire +7.59%
Feb-15-17 08:42AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -21.20%
Feb-06-17 10:30AM  Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Accesswire -5.46%
Jan-30-17 12:26PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-26-17 08:59AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -10.24%
Jan-23-17 08:00AM  Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017 PR Newswire
Jan-18-17 08:00AM  New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium PR Newswire -14.43%
Jan-12-17 08:30AM  Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort PR Newswire +8.40%
Jan-06-17 04:04PM  DryShips, Merrimack Tumble into Fridays 52-Week Low Club -29.34%
Nov-30-16 08:30AM  Delcath Systems to Present at the 9th Annual LD Micro Main Event Accesswire
Nov-18-16 01:04PM  DELCATH SYSTEMS, INC. Financials
Nov-14-16 12:27PM  Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 +6.42%
Nov-11-16 07:30AM  Delcath Announces Third Quarter Financial Results PR Newswire +15.43%
Nov-10-16 04:42PM  DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report +7.64%
Oct-18-16 04:32PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Delcath Issues Letter to Stockholders PR Newswire
Oct-17-16 08:30AM  Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy PR Newswire
Oct-12-16 09:08AM  Delcath Announces First European Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases PR Newswire
Oct-11-16 08:57AM  Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases PR Newswire
Oct-05-16 04:36PM  Delcath To Present At The Dawson James Securities Growth Stock Conference PR Newswire +7.06%
Oct-04-16 08:43AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Finan
Sep-30-16 12:50PM  Heres Why These Five Stocks Are on the Move Today at Insider Monkey -28.26%
09:22AM  Delcath Prices Underwritten Public Offering of Common Stock and Warrants Business Wire
Sep-29-16 05:40PM  Delcath Announces Proposed Public Offering of Common Stock and Warrants PR Newswire
Sep-19-16 09:50AM  Delcath Sponsors Ocular Melanoma Foundation Patient Retreat PR Newswire -6.26%
Sep-14-16 08:30AM  Data Supporting CHEMOSAT Presented at the Cardiovascular and Interventional Radiology Society of Europe Conference Business Wire
Sep-12-16 04:05PM  Delcath To Present At The 2016 Aegis Growth Conference PR Newswire
08:42AM  Researchers at leiden univeristy medical center receive outstanding service award for Publication on Delcath's Melphalan/HDS PR Newswire
Aug-18-16 10:44AM  Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-16-16 08:00AM  Delcath Announces Second Quarter Financial Results PR Newswire
Aug-15-16 04:11PM  DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report
Aug-08-16 04:09PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events -7.76%
Jul-21-16 06:04AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. o -18.51%
Jul-18-16 08:00AM  Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016 PR Newswire
Jul-07-16 08:00AM  Outcomes Study On Delcath's Melphalan/HDS In The Treatment Of Hepatic Metastases To Be Published In Cancer Control PR Newswire
Jul-06-16 08:00AM  European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting PR Newswire +8.70%
Jun-23-16 08:00AM  Delcath European Patient Education Website Receives Prestigious Digital Health Award PR Newswire
Jun-17-16 04:17PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal
Jun-15-16 08:00AM  Delcath Announces Acceptance Of Abstract For Presentation At 6th European Post-Chicago Melanoma/Skin Cancer Meeting PR Newswire +8.33%
Jun-07-16 08:31AM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme -21.21%
08:00AM  Delcath Issues $35 Million in Senior Convertible Notes to Support Melphalan/HDS Clinical Development and CHEMOSAT European Commercialization PR Newswire
Jun-01-16 08:00AM  Delcath Announces Launch of CHEMOSAT at the HM Sanchinarro University Hospital in Madrid PR Newswire
May-31-16 08:00AM  Delcath to Present at the 6th Annual LD Micro Invitational PR Newswire
May-26-16 11:17AM  Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016
May-04-16 05:09PM  DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report -6.25%
08:00AM  Delcath Announces First Quarter Financial Results PR Newswire
May-03-16 08:00AM  Leading U.S. Cancer Centers Join Delcath's Focus Phase 3 Trial For Patients With Hepatic Dominant Ocular Melanoma PR Newswire +6.67%
Apr-08-16 08:00AM  Delcath Announces First CHEMOSAT┬« Procedures In Turkey PR Newswire +11.11%
Apr-07-16 04:17PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-23-16 04:34PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
10:37AM  Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-22-16 02:20PM  Delcath Systems, Inc. :DCTH-US: Earnings Analysis: 2015 By the Numbers
Mar-21-16 08:18AM  Delcath Announces 2015 Fourth Quarter and Full Year Financial Results at noodls
08:00AM  Delcath Announces 2015 Fourth Quarter and Full Year Financial Results PR Newswire
Mar-18-16 02:12PM  DELCATH SYSTEMS, INC. Files SEC form 10-K, Annual Report -6.06%
Mar-07-16 08:00AM  Delcath to Present at the 28th Annual ROTH Conference PR Newswire
Feb-11-16 08:30AM  Delcath announces Engagement of Lars E. Birgerson, M.D., Ph. D as global medical consultant PR Newswire
Feb-10-16 04:22PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand +8.00%
08:30AM  Delcath Announces Beginning Of Patient Enrollment In Phase 3 Focus Trial PR Newswire
Feb-04-16 08:00AM  Delcath Systems to Present at Upcoming Investor Conferences PR Newswire
Jan-22-16 04:26PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-20-16 08:00AM  Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma PR Newswire -8.70%
Jan-19-16 08:00AM  MicroCap Review Magazine Winter/Spring 2016 Issue Now Available Marketwired
08:00AM  Delcath Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma PR Newswire
Jan-15-16 10:17AM  Delcath To Present At NobleCon12 Investor Conference PR Newswire
Jan-11-16 08:30AM  Review of Delcath Melphalan/HDS System Published in "Cardiovascular & Interventional Radiology" PR Newswire
Dec-09-15 08:59AM  Delcath Prior Phase 3 Trial Results Published In Annals Of Surgical Oncology PR Newswire +15.00%
Dec-08-15 08:00AM  Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology PR Newswire
Dec-02-15 08:00AM  Delcath Announces CHEMOSAT Treatment Milestones In Europe PR Newswire -6.00%
Nov-25-15 04:07PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-17-15 10:00AM  Delcath Systems Inc Conference Call to discuss Business Update scheduled for 10:00 am ET today -9.09%
Nov-11-15 09:40AM  Delcath Systems To Host Business Update Conference Call On November 17, 2015 PR Newswire
Nov-10-15 04:10PM  DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report
08:30AM  Delcath Reports 2015 Third Quarter Financial Results PR Newswire
Nov-02-15 08:30AM  Data Supporting Delcath's CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress PR Newswire
Oct-15-15 05:02PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +10.71%
11:07AM  Delcath Announces First Patient Treated In ICC Cohort Of Global Phase 2 HCC Trial Program PR Newswire
Oct-14-15 08:00AM  Delcath Phase 3 Trial Results To Be Published In Annals Of Surgical Oncology PR Newswire +5.66%
Oct-09-15 04:53PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +18.75%
08:30AM  StockNewsNow.com Publishes New SNNLive Video Interview With Delcath Systems, Inc. Marketwired
Oct-08-15 08:30AM  Delcath Announces National Reimbursement Coverage For CHEMOSAT Procedures In Germany PR Newswire +6.67%
Oct-06-15 04:21PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
08:00AM  Delcath Systems Appoints CEO Jennifer Simpson To Board Of Directors PR Newswire
Oct-02-15 10:51AM  Delcath Systems, Inc. Earnings Q2, 2015
Sep-30-15 08:00AM  Data Supporting Delcath's Chemosat System Presented At The Cardiovascular and Interventional Radiology Society Annual Meeting PR Newswire
Sep-28-15 08:00AM  Retrospective Study Examining Delcath's CHEMOSAT And Isolated Hepatic Perfusion Presented At ECCO Annual Meeting PR Newswire -14.00%
Sep-09-15 08:30AM  Delcath Announces Acceptance Of Abstract For Presentation At RSNA Annual Meeting PR Newswire -6.00%
Sep-04-15 07:12AM  3 Breakout Stocks Under $10 to Trade Now at TheStreet +19.05%
Sep-03-15 04:41PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-02-15 08:00AM  Delcath To Present At The 17th Annual Rodman & Renshaw Conference PR Newswire -6.98%
Aug-31-15 04:49PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +10.00%
Aug-14-15 04:08PM  DELCATH SYSTEMS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
Aug-12-15 11:30AM  ICU Medical, Inc.: Leads amongst peers with strong fundamentals
Aug-07-15 08:12PM  10-Q for Delcath Systems, Inc. at Company Spotlight +6.00%
Aug-05-15 04:39PM  DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report
08:00AM  Delcath Reports 2015 Second Quarter Financial Results PR Newswire
Aug-04-15 08:00AM  Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress PR Newswire
Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.